The Year in Cardiovascular Medicine: 2025
2025 was a pivotal year for cardiology, marked by significant advancements and paradigm shifts in treatment, risk assessment, and clinical practice. The field witnessed groundbreaking research and the release of life-changing guidelines, reshaping the landscape of cardiovascular medicine.
Challenging Long-Held Assumptions: Aspirin's Decline
One of the most notable developments was the reevaluation of aspirin's role in cardiovascular health. Long-standing assumptions were challenged by new research, prompting a rethinking of its routine use. The Medical Republic reported on several large studies, including findings that routine aspirin use does not provide benefits that outweigh the increased risks. Researchers concluded that lifelong aspirin use was based on outdated evidence, and superior antiplatelet therapies like clopidogrel may replace aspirin as the preferred choice. A clinical trial had to be halted early due to excess deaths, leading to a reevaluation of prescribing practices.
Single-Pill Combinations and Hypertension Treatment
2025 also saw a strong push for single-pill combinations (SPCs) and fixed-dose combinations (FDCs) as first-line hypertension treatment. Urgent calls were made for changes to the Pharmaceutical Benefits Scheme (PBS) to reflect these advancements. However, despite the article's publication in August, PBS restrictions remain in place, and updates to the Australian Hypertension Guidelines, expected at the end of the year, have yet to be released.
CRISPR Gene Editing Breakthrough
Australian researchers made a significant breakthrough in CRISPR gene editing, conducting the first in-human trial to manage cholesterol. A single injection of editing tools resulted in substantial reductions in both cholesterol and triglycerides, marking the first therapy to achieve this simultaneously. This breakthrough was hailed as a potential game-changer for managing mixed lipid disorders.
European Society of Cardiology Recommendations
The European Society of Cardiology and the European Atherosclerosis Society released new international guidelines for dyslipidaemia management. These recommendations introduced a more aggressive approach to lipid-lowering regimens, moving away from the traditional low and slow tactic. The guidelines emphasized the importance of utilizing Lp(a) for heart disease prevention, a long-overlooked risk factor. Research published in 2025 suggested that routine screening for Lp(a) could prevent a significant number of heart attacks, strokes, and early deaths.
PCSK9 Inhibitors: Cholesterol Management Revolution
The American Heart Association's annual scientific sessions showcased multiple studies on PCSK9 inhibitors, a groundbreaking treatment for cholesterol management. One study found that combining PCSK9 inhibitors with statins provided additional protection, reducing the risk of cardiovascular death, heart attack, or ischemic stroke by over 25%. Cardiologists from Italy, Germany, and the US, in a viewpoint published in the European Heart Journal, praised the impact of pivotal randomized clinical trials on interventional cardiology in 2025, highlighting their role in reshaping daily practice and refining long-term expectations for percutaneous therapies.
These studies and guidelines collectively represent a significant leap forward in cardiovascular medicine, challenging long-held assumptions, and introducing innovative treatments and risk assessment methods.
